BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study

BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after

Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians

Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,

Environmental and Lifestyle Hematology: How Air Pollution and Chronic Stress Influence Hematopoiesis, Inflammation, and Vascular Risk

Environmental and Lifestyle Hematology: The Influence of Air Pollution and Chronic Stress on Hematopoiesis, Inflammation, and Vascular Risk Review Abstract Purpose: This review examines how fine particulate air pollution and chronic psychosocial stress may influence hematopoiesis, inflammatory leukocyte production, coagulation biology, clonal hematopoiesis, and cardiovascular risk.

VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know

VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know   Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides a comprehensive review of VEXAS syndrome; a newly recognized, adult-onset autoinflammatory condition with a genetic basis and complex multisystem involvement, carrying significant implications for hematologists, rheumatologists, and other specialists. First

Plasmapheresis in TTP Mimics: When Are We Getting It Wrong?

Plasmapheresis in TTP Mimics: When Are We Getting It Wrong?   Check back later for a possible video summary. Videos are created for most articles.     Introduction Plasmapheresis has revolutionized the treatment of thrombotic thrombocytopenic purpura (TTP), reducing mortality rates from nearly 100% to less than 10–20%. Despite this progress, diagnostic uncertainty remains a

Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond

Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond   Check back later for a possible video summary. Videos are created for most articles.   Abstract This paper provides an in-depth review of monoclonal antibody (mAb) therapies in the treatment of relapsed multiple myeloma (MM), with a particular focus on bispecific antibodies

IRON DEFICIENCY’S IMPACT ON NEW-ONSET CHRONIC HEART FAILURE OUTCOME: DANISH HEART FAILURE REGISTRY INSIGHTS

IRON DEFICIENCY’S IMPACT ON NEW-ONSET CHRONIC HEART FAILURE OUTCOME Please like and subscribe if you enjoyed this video :-)   Introduction Iron deficiency (ID) is a common condition affecting more than half of patients with chronic heart failure (HF). It is linked to reduced

Rusfertide Treatment For Elevated Red Blood Cell Production

Rusfertide Treatment For Elevated Red Blood Cell Production Overview Polycythemia vera is a chronic myeloproliferative disorder marked by elevated red blood cell production. Rusfertide, a peptide mimetic of the iron-regulating hormone hepcidin, has been developed to limit iron availability for erythropoiesis. However, its safety and efficacy in patients with polycythemia vera who

BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study